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The objective of this study was to develop a bovine viral diarrhea virus type 2 (BVDV-2) 
challenge model suitable for evaluation of efficacy of BVDV vaccines; a model that mim-
ics natural infection and induces clear leukopenia and viremia. Clinical, hematological 
and virological parameters were evaluated after infection of two age groups of calves (3 
and 9 months) with two BVDV-2 strains (1362727 and 502643). Calves became pyrexic 
between 8 and 9 days post inoculation and exhibited symptoms, such as nasal dis-
charge, mild depression, cough, and inappetence. Leukopenia with associated lymph-
openia and neutropenia was evident in all groups with lowest leukocyte and lymphocyte 
counts reached 8 dpi and granulocyte counts between 11 and 16 dpi, dependent on 
the strain and age of the calves. A more severe thrombocytopenia was seen in those 
animals inoculated with strain 1362727. Leukocyte and nasal swab samples were posi-
tive by virus isolation, as early as 3 dpi and 2 dpi respectively, independent of the inocula 
used. All calves seroconverted with high levels of BVDV-2 neutralizing antibodies. BVDV 
RNA was evident as late as 90 dpi and provides the first evidence of the presence of 
replicating virus long after recovery from BVDV-2 experimental infection. In summary, 
moderate disease can be induced after experimental infection of calves with a low titer 
of virulent BVDV-2, with leukopenia, thrombocytopenia, viremia, and virus shedding. 
These strains represent an attractive model to assess the protective efficacy of existing 
and new vaccines against BVDV-2.
Keywords: bovine viral diarrhea virus type 2, experimental infection, pathogenesis, virus persistence, challenge 
model
inTrODUcTiOn
Bovine viral diarrhea virus (BVDV) is a major pathogen of cattle and also infects a diverse range 
of ruminants worldwide (1). It is a member of the family Flaviviridae, genus pestivirus that also 
includes border disease virus, classical swine fever virus, and atypical pestiviruses. BVDV exists as 
two genotypes; BVDV-1 and -2, with a tentative third genotype, atypical bovine pestiviruses (2). 
BVDV-1 and BVDV-2 have been further subdivided into sub-genotypes based on their genetic 
characteristics (3).
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Bovine viral diarrhea virus infection in cattle causes a variety 
of clinical representations, from an asymptomatic infection to 
fatal disease (4). Typically, acute infection in postnatal calves 
causes a mild transient disease lasting 10–14  days consist-
ing of diarrhea, inappetence, respiratory complications, and 
an overall loss of condition. In addition, a mild pyrexia and 
transient leukopenia are apparent for 2–3 days with serocon-
version usually before 21 days post-infection (dpi). Infectious 
virus can be detected in blood and bodily secretions from 
calves as early as 4  dpi and up to 15  days. BVDV RNA has 
been detected by sensitive RT-PCR techniques long after the 
acute infection has cleared. This has raised questions about 
the virus-free status of animals that have cleared the initial 
infection and raised an antibody response (5–7). It has also 
been reported to reduce milk yields and impact on reproduc-
tive performance. Acute BVDV infection of in-dam heifers 
can give rise to the birth of persistently infected (PI) calves, 
which are able to shed large quantities of virus and, thus, infect 
susceptible herd mates. The majority of BVD control/eradica-
tion programs aim to identify these animals through the use 
of appropriate diagnostic assays and remove them from herds. 
This in conjunction with vaccination schedules reduces hori-
zontal transmission to naïve herd mates and prevents vertical 
transmission to the fetus. Therefore, it is necessary to ensure 
that BVD vaccines afford protection to circulating strains of 
BVDV-1 and -2.
BVDV-2 strains were first associated with a severe hemor-
rhagic disease with high mortality in cattle in Canada and 
USA but strains causing milder disease have been detected 
subsequently (8, 9). Over the past 10 years, BVDV-2 has been 
introduced to Europe through the importation of animals and 
contaminated products. Recent outbreaks have been reported in 
Germany (10), Poland (11), and Spain (12). A range of patho-
genicity of strains has been reported for both BVDV-2 and -1 
(13–15). Dose and virulence of strains, together with the age 
and immunocompetence of the naïve animal have all been impli-
cated as having an effect on the pathogenicity of disease. Indeed 
recent studies have found that a more severe clinical disease was 
observed if the calf either received a high dose of BVDV-1, or 
was immunocompromised by the use of dexamethasone or was 
only 3 months old (7).
In this study, we aimed to establish an intranasal BVDV-2 
challenge model that would allow the study of pathogenicity 
of disease and evaluation of efficacy of BVDV vaccines without 
causing severe clinical disease or mortality in naïve animals. 
If a potential challenge strain caused a mild disease in the 
field, experimentally it may fail to provide clear and measur-
able outcomes of disease, such as pyrexia, thrombocytopenia, 
and leukopenia. However, a highly virulent field strain may 
generate these markers of disease but the humane end-point 
may be reached too soon for the efficacy of a vaccine to be fully 
evaluated. Thus, using two BVDV-2 strains, the progression of 
disease was monitored using an extensive clinical scoring sys-
tem, virus isolation techniques, and by studying immunological 
parameters. Evidence of the presence of viral RNA persisting 
long after recovery from BVDV-2 infection was additionally 
evaluated.
MaTerials anD MeThODs
Viruses
The non-cytopathic BVDV-2 strain, 502643, was the first case of 
BVDV-2 isolated in the UK from a bull suffering from ill-thrift 
that subsequently died (16). The BVDV-2 strain, 1362727, was 
isolated from a UK farm in 2006 where the cattle exhibited severe 
clinical symptoms with associated death in many cases (17). Virus 
strains were propagated four passages on fetal bovine turbinate 
(fBT) cells. After 5 days incubation, virus was harvested and titred 
on fBT cells (16).
study Design
Experiments were carried out on clinically healthy calves aged 
11–13  weeks (Danish Holstein; male and female calves) or 
9 months old (Danish Holstein or Danish Red; female calves). 
The calves were confirmed as seronegative for antibodies 
against BVDV (HerdChek® BVDV Antibody ELISA, IDEXX 
Laboratories, Wetherby, UK) and tested negative in a BVDV-
specific RT-PCR (Penrith, APHA). Six calves of 11–13  weeks 
old and five calves of 9 months old were inoculated intranasally 
using intranasal applicator with 105.0 TCID50 of BVDV-2 strain 
1362727 (groups 1A and 1B, respectively). Two groups of five 
calves (11–13  weeks old and 9  months old) were inoculated 
intranasally with 104.8 TCID50 of BVDV-2 strain 502643 
(groups 2A and 2B, respectively). The different inocula were 
administered in a 2 ml volume with 1 ml delivered per nostril. 
The inoculation dose was confirmed through back titration of 
the inocula. Animals were monitored once daily from 2  days 
prior to inoculation, until 21  dpi for clinical signs and rectal 
temperatures were recorded. During these clinical observations, 
calves were scored for nasal discharge, ocular discharge/con-
junctivitis, cough, dyspnea, depression, appetite, diarrhea, and 
dehydration each on a scale from 0 to 3 (absent, mild, moderate, 
or severe) according to the scoring system used previously (7). 
The 3-month-old animals inoculated with the BVDV-2 strains 
(group 1A and 2A) were maintained to assess long-term infec-
tion while the group 1B and 2B animals were euthanized at 
21 dpi. One or two animals from the group 1A and 2A calves 
were euthanized for post-mortem examinations at 28, 55, and 
90 days post inoculation.
ethics statement
The animal study was conducted at Contract Research Unit of 
the Royal Veterinary College under Home Office License number 
PPL 70/6459 Protocol 19b5 and approved by the Pfizer Animal 
Health Animal Welfare Committee.
Virus isolation
Nasal swabs and heparinized blood samples were collected from 
all animals daily from 0 to 14 dpi and on 16 dpi. To isolate virus 
from leukocytes, blood was centrifuged at 1500 × g for 10 min 
and visible buffy coat material aspirated. Contaminating eryth-
rocytes were lysed by addition of 10 ml of Pharmlyse Buffer (BD 
Biosciences, Oxford, UK) and incubation for 10  min at room 
temperature (RT) before being washed three times in HBSS (Life 
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Technologies, ThermoFisher Scientific, Paisley, UK). Virus isola-
tion was carried out on fBT cells as described (7).
serum neutralization Tests and BVDV 
antibody elisa
Blood samples without anti-coagulant were collected on 0 and 
21 dpi. The samples were left at RT for 2 h to clot prior to centrifu-
gation at 1500 × g for 10 min. Samples were tested for BVDV-2 
neutralizing antibodies by serum neutralization test, using a 
heterologous strain, NADL (18). BVDV-specific antibody was 
detected in serum samples using a commercial indirect ELISA 
(HerdChek® BVDV Antibody ELISA, IDEXX Laboratories, 
Wetherby, UK) performed according to the manufacturer’s 
protocol.
hematology
EDTA-treated blood samples for platelet and differential leu-
kocyte counts were collected daily from −2 to 14  dpi and on 
16, 18, and 20 dpi. Platelet and leukocytes were enumerated by 
volumetric flow cytometry. In brief, EDTA blood was centrifuged 
at 200 × g for 1 min and 5 µl of platelet-rich plasma was diluted 
in 2  ml of CellFIX solution (BD Biosciences). The number of 
platelets was determined using a volumetric flow cytometer 
(MACSQuant Analyzer; Miltenyi Biotec, Bisley, UK). For total 
leukocyte counts, EDTA blood was stained with anti-CD45-FITC 
mAb clone 1.11.32 (IgG1) (Bio-Rad Antibodies, Oxford, UK) and 
cell counts were obtained by gating FITC positive events (19).
rT-Pcr Detection of BVDV rna
EDTA blood samples were taken from group 1A and group 
1B calves, that were remaining on 28, 42, 55, 70, and 90  dpi. 
RNA was extracted from 140  µl of blood using the QIAamp 
viral RNA extraction kit (Qiagen, Crawley, UK) according to 
the manufacturer’s procedure. Viral RNA was detected using a 
one-step short-target real-time RT-PCR assay executed for 50 
cycles, which detects both strands of BVDV RNA (20). Selected 
RT-PCR positive samples were further tested using a two-step 
negative-strand-specific RT-PCR that only detects the presence 
of the replicative intermediate evident during BVDV genome 
replication (7).
statistical analysis
Clinical scores were analyzed by Kruskal–Wallis ranking test. 
Statistical significance between groups and between pre- and 
post-challenge levels was determined using a one-way ANOVA 
test. A Bonferroni adjusted p-value of 0.007 was considered 
indicative of significance.
resUlTs
Calves inoculated with either BVDV-2 strain, 1362727 or 502643, 
exhibited nasal discharge, coughing, mild depression, and inap-
petence with a peak in mean clinical score between 8 and 11 dpi 
(Figure 1A). All calves in all groups developed mild to moderate 
clinical disease. Group 1A calves (3-month-old calves inoculated 
with strain 1362727) achieved a higher mean clinical score that 
was sustained for a longer period compared to the group 1B 
calves (9  months old; 1362727). By contrast, group 2B calves 
(9-month-old calves inoculated with strain 502643) reached a 
higher mean clinical score than group 2A calves (3 months old; 
502643). Although, the differences in clinical score observed were 
not statistically significant (p =  0.305). After inoculation with 
either BVDV-2 strains, all animals independent of age exhibited 
pyrexia (>39.5oC) by 8 dpi with this lasting for 2 days in majority 
of the animals (Figure 1B).
Hematology counts were calculated as a percentage of the 
pre-inoculation baseline. All groups showed a decrease, albeit 
not statistically significant compared to pre-inoculation levels 
(p =  0.14), in mean platelets count and reached lowest levels 
between 11 and 13 dpi (Figure 2A). Group 1B animals showed 
the greatest drop in counts to as low as 38% of the pre-inoculation 
level at 11 dpi. Platelets count increased toward baseline levels as 
the study progressed. Based on the mean total leukocyte count, 
all groups of calves exhibited a transient leukopenia during the 
study (Figure 2B). Calves inoculated with strain 1362727 showed 
the more marked response compared to 502643 inoculated calves 
with levels dropping on 8 dpi to as low as 45 and 52% of the base-
line level for groups 1A and 1B, respectively. There was a minimal 
decrease in mean total leukocyte count for group 2B calves due 
to only two of the five animals showing any notable decrease in 
total leukocyte counts. In all groups, mean lymphocyte counts 
decreased to lowest levels at 8  dpi (Figure  2C) with group 1B 
animals showing the greatest drop to 47% of pre-inoculation lev-
els, although this was not significant compared to pre-inoculation 
levels (p = 0.15). Granulocyte levels initially dropped to the low-
est level at 11 dpi in all groups (Figure 2D). Although a further 
decrease to 27% of the pre-inoculation baseline was reached for 
group 1B at 16 dpi. All groups showed monocytosis with highest 
counts ranging from 156– 212% dependent on the inocula and 
the age of calves (Figure 2E).
Virus was isolated from nasal swabs and leukocytes isolated 
from EDTA blood samples (Table 1; Table S1 in Supplementary 
Material). Virus was isolated from nasal swabs from group 1A 
calves inoculated with BVDV-2 strain 1362727 from 2 to 14 dpi 
and for group 1B animals from 4 to 10 dpi and 13 to 14 dpi. For 
the 502643 strain, virus isolations from nasal swabs were positive 
2, 4–10, and 16 dpi for animals in group 2A with isolations from 
all animals on 5 and 9 dpi and from the group 2B animals from 
4 to 10 dpi and 12–13 dpi. Virus was isolated from leukocytes 
on 3–12, 14, and 16 dpi for the group 1A animals with isolations 
from all animals on 5, 7, and 8 dpi. For the group 1B calves, virus 
was isolated on 5–11 and 13 dpi with all animals testing positive 
on 5 dpi. Virus was isolated on 5–9, 11–12, and 16 dpi for the 
group 2A calves with isolations from all animals on 5 and 8 dpi. 
For the group 2B animals, virus was isolated on 3–14 dpi with all 
animals being positive on 8 dpi.
Blood samples were taken from all groups of animals on 0 
and 21 dpi. For all groups, calves had seroconverted by 21 dpi 
(Figure  3A). There was no significant difference between the 
mean neutralizing antibody titers for any groups. In all groups, 
BVDV-specific antibody levels increased over the course of the 
study to levels that were consistent with seroconversion to the 
virus (Figure 3B).
FigUre 1 | Assessment of the clinical signs and pyrexia induced following experimental infection of calves with BVDV-2 isolates. Mean clinical scores ± SEM  
(a) and rectal temperatures ± SEM (B) following inoculation with BVDV-2 isolates 1362727 (Group 1) and 502643 (Group 2) were assessed in 3-month (Groups 1A 
and 2A) and 9-month-old calves (Groups 1B and 2B).
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To investigate the presence of replicating virus after the ani-
mals had recovered from an acute infection, group 1B and group 
2B animals were maintained up to 90 dpi. Individual EDTA blood 
samples were tested using the short-target RT-PCR (20) and RNA 
positive samples were further tested using the negative-strand-
specific RT-PCR (7). One of the three calves remaining at 90 dpi 
was RNA positive when using the short-target PCR which detects 
both the viral genome and the replicative intermediate. This calf 
from group 2B also tested positive as late as 70  dpi using the 
negative-strand-specific RT-PCR which detects only the replica-
tive intermediate (Table 2). Another calf from group 2B was RNA 
positive at 55 dpi and tested positive using the negative-strand-
specific RT-PCR at 42  dpi. Of the three calves from group 1B 
tested using the short-target RT-PCR, 3 out of 3 were viral RNA 
positive at 28 dpi and only 1 out of 3 at 42 dpi. These samples were 
not tested using the negative-strand-specific RT-PCR so it is not 
clear if there was actively replicating virus at these time-points.
DiscUssiOn
The purpose of this study was to develop an experimental chal-
lenge model for assessing the efficacy of BVDV vaccines using a 
BVDV-2 strain that would produce measurable outcomes, such 
as leukopenia and viremia, without severe clinical disease. The 
second area was to investigate the persistence of BVDV-2 since 
infections of calves with BVDV-1 resulted in prolonged viremia 
and replication (6, 7). During the study, mild to moderate clini-
cal symptoms were observed with a peak in clinical symptoms 
at around 8–10 dpi. However, one animal in group 1A displayed 
significant nasal discharge at 6  dpi. All the group 2A calves 
received an anti-inflammatory injection at 11 dpi due to dullness, 
pyrexia, and nasal discharge. Nevertheless, there was no marked 
difference in mean clinical score, leukocyte, or platelet counts 
between this group and the group 2B calves that were infected 
with the same BVDV strain at the same dose. The requirement 
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FigUre 2 | Continued
for veterinary intervention may be attributed to the younger age 
of the calves in group 2A compared to 2B. A single group 1B 
calf required veterinary intervention during the study possibly 
due to secondary opportunistic bacterial infection that may have 
already been present subclinically in the animal before the onset 
of the study. This calf exhibited a prolonged pyrexia, inappetance 
TaBle 2 | Ct values for short-target and negative-strand RT-PCR.
Virus Pcr Days post inoculation
28 43 55 70 90
BVDV-2 (502643) Short targeta 36.76 40.00 36.01 38.19 40.91
Negative strandb 41.15 38.85 37.61 41.27 No Ct
aOne-step real-time RT-PCR detects total viral RNA.
bTwo-step real-time RT-PCR detects only negative-strand viral RNA.
FigUre 3 | Serological responses following experimental infection of calves with BVDV-2 isolates. Mean serum neutralizing antibody titers (log2 transformed) 
measured at 21 dpi (a) and BVDV antibody levels (OD values ± SEM) (B) are plotted for calves inoculated with BVDV-2 isolates 1362727 (Group 1) and 502643 
(Group 2).
TaBle 1 | Summary of Virus isolation data.
group Virus strain age (months) nasal swabs leukocytes
range of detection (days) Peak detection (days) range of detection (days) Peak detection (days)
1A BVDV-2 (1362727) 3 2–14 – 3–16 5, 7, 8
1B BVDV-2 (1362727) 9 4–14 – 5–13 5
2A BVDV-2 (502643) 3 2–16 5, 9 5–16 5, 8
2B BVDV-2 (502643) 9 4–13 – 3–14 8
FigUre 2 | Assessment of hematological parameters following experimental infection of calves with BVDV-2 isolates. Mean values ± SEM for platelets (a), total 
leukocytes (B), lymphocytes (c), granulocytes (D), and monocyte (e) counts are displayed as a percentage of pre-inoculation baseline counts following inoculation 
with BVDV-2 isolates 1362727 (Group 1) and 502643 (Group 2) in 3-month (Groups 1A and 2A) and 9-month-old calves (Groups 1B and 2B).
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and nasal discharge, and lower leukocyte and platelet counts 
compared to others group 1B calves. This calf was treated with 
antibiotics and anti-inflammatories and clinical signs resolved 
and leukocyte and platelet counts returned to baseline levels in 
line with the other calves.
During the study, leukopenia was evident in all groups of 
calves with associated lymphopenia and neutropenia which is 
consistent with other experimental intranasal infection with 
7Strong et al. BVDV-2 Challenge Model
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both high and low virulent BVDV-2 isolates with the greater 
decrease associated with the high-virulence strains (21, 22). 
Indeed, inoculation with strain 1362727 promoted a greater 
decrease in total leukocyte counts compared to strain 502643 
consistent with the more virulent nature of strain 1362727 
compared to strain 502643. All calves in groups 1A and 1B, 
inoculated with 1362727, developed thrombocytopenia with 
levels recovering by 3  weeks post inoculation. Little such 
changes were seen in group 2A and 2B animals, inoculated with 
502653, even though these animals showed clear signs of infec-
tion. Thrombocytopenia has been associated with experimental 
infection of calves with either BVDV-1 or -2 isolates (7, 22–25) 
and in comparative studies of high and low virulent strains 
thrombocytopenia has not developed in calves inoculated with 
a low virulent strain (22). The monocytosis associated with 
BVDV infection has been described previously during a study 
of naturally BVDV-1 infected calves (26). However, this is in 
contrast to an experimental intranasal infection with BVDV-2 
where a monocytopenia was reported (27).
Virus was isolated from both nasal swabs and peripheral 
blood leukocytes from each animal regardless of the inocu-
lated strain or age of animals, which is consistent with previous 
studies of acute BVDV infection (7). Although in this study no 
naïve “in-contact” animals were included, the presence of virus 
in the nasal swabs shows the potential for horizontal transmis-
sion. The peak of virus isolation from both nasal swab and 
leukocyte samples coincided with the peak of clinical signs and 
pyrexia observed in all groups. The presence of BVDV RNA 
after the clinical signs have resolved and animals have serocon-
verted has been reported previously (6, 7, 28–30). The presence 
of the replicative intermediate as late as 70  dpi is consistent 
with our previous work with experimental BVDV-1 infection 
(7) and this indicates that the virus is still replicating long after 
the calves have recovered from the initial clinical infection. 
It is not clear from this study if these calves were capable of 
shedding and/or transmitting virus as nasal swabs were not 
taken at these time points and naïve animals were not present. 
However, previous studies with a BVDV-1 strain demonstrated 
viral RNA in nasal swabs as late as 80  dpi. Although, there 
was no transmission of virus to two naïve calves introduced 
at 50 dpi and maintained until the end of the study (7). Other 
experimental infections with BVDV-1 strains have also been 
unable to demonstrate the ability of these viral RNA positive, 
antibody-positive calves to transmit virus to BVDV-naïve 
herd mates (6). Although studies have shown that viral RNA-
positive semen and blood samples collected from animals that 
have recovered from the initial infection can infect naïve cattle 
when injected intravenously (5, 6). This raises questions about 
the BVDV-free status of calves that have recovered from acute 
infections and mounted an antibody response and whether 
they pose a risk to BVDV-naïve animals. This risk may be lower 
than that posed by PI calves, which shed large amounts of virus 
throughout their life. However, these PI calves are identified 
and removed from herds and these recovered calves may act 
as “virus carriers,” thus providing a potential source of infec-
tion for naïve herd mates in a herd deemed to be BVDV free. 
Further studies need to be carried out to try to understand the 
mechanism by which the virus replicates long after the acute 
infection and the impact that this may have on BVDV-naïve 
herd mates in the field particularly during BVDV control 
programs.
The experimental infection reported here for strain 1362727 
showed a milder progression of disease in comparison to the 
severe clinical disease observed in the original field infections 
(13, 31). Previous studies have proposed that other factors may 
have an impact on the progression of the disease in the field, 
such as environmental factors, immunocompetence, nutritional 
status, and pre-existing infections. This is supported by our 
previous study, where a 105.55 TCID50 dose of a highly pathogenic 
field strain of BVDV-1 gave rise to a moderate clinical outcome 
from which the calves would recover rather than succumb as in 
the original field situation. Interestingly, inoculation with strain 
502643 originally isolated from a persistently infected bull with 
ill-thrift which was present in an asymptomatic herd gave rise to 
a measurable clinical outcome.
The potential for using either of these viruses as challenge 
strains for BVDV vaccine efficacy studies requires that there is 
measurable clinical disease that does not pose problems for ani-
mal welfare. This was apparent for strains 1362727 and 502643 as 
both these strains generated disease with overt clinical symptoms, 
such as pyrexia, nasal discharge, and inappetence, in all calves in 
both age groups. Infectious virus was isolated from nasal swabs 
and leukocyte samples from calves inoculated with either strain 
independent of the age of the calves. However, a higher number 
of the calves inoculated with strain 1362727 achieved a higher 
than 40% decrease in both leukocyte (group 1A—6 out of 6; 
group 1B—4 out of 5) and platelet counts (group 1A—4 out of 6; 
group 1B—4 out of 5) compared to those calves inoculated with 
strain 502643 in which only 2 out of 5 calves demonstrated this 
decrease. This would suggest that strain 1362727 is an attractive 
candidate for future efficacy studies as it demonstrated measur-
able clinical parameters but these were not severe enough to 
warrant euthanasia of any of the calves.
In conclusion, we present a robust experimental challenge 
model for BVDV-2 which induces a range of clinical signs, meas-
urable hematological alterations, and viral loads in peripheral 
blood and secretions. As such these models will aid in the further 
characterization of BVDV-2 infections and provide a challenge 
system with which to assess the protective efficacy of existing and 
novel BVDV vaccines. It can also be used for further host–patho-
gen interaction studies to resolve the nature of the long-term 
replication of BVDV in host animals.
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